US equities |
MU $1,055.32 ▼-3.00% NVDA $233.27 ▼-1.77% SNDK $1,616.64 ▼-4.48% AMD $626.56 ▼-2.99% PLTR $197.59 ▲+1.79% INTC $108.09 ▼-4.45% SPCX $161.87 ▼-3.42% META $714.75 ▼-0.91%
FinancialContent

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.140 -0.040 (-3.39%)
Delayed Quote Updated: 12:50 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Private Placement of $2,715,000
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology to Present at Biotech Showcase 2025
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Private Placement of Approximately $950,000
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces $2.44 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
News headline image
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
From MAIA Biotechnology
Via Business Wire
News headline image
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
Via AB Newswire
News headline image
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients ↗
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
News headline image
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
From MAIA Biotechnology, Inc.
Via Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
News headline image
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
--News Direct-- 
Via News Direct
Topics Death
News headline image
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
Via AB Newswire
News headline image
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
From MAIA Biotechnology, Inc.
Via Business Wire
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >